Organisation
Intellectual Property
Administrative Office
Projects
1 - 10 of 16
- HTS to discover direct-acting small molecule inhibitors of henipavirusesFrom16 Nov 2022 → TodayFunding: Foreign private sponsor - undefined
- PHGDH-ASM: Phosphoglycerate dehydrogenase (PHGDH) activators as novel antiseizure medications (ASM) with dual mode of actionFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- VirusBank platform (state-of-the-art research platform for increased preparedness against viral epidemics and pandemics)From1 Jan 2022 → TodayFunding: Ministery of Economical Affairs
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- MATATUM: Validation and druggability development of macrophage-specific targets in the tumor microenvironment.From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project
- Valorization of novel strategies for the prevention of viral infection and inhibition of viral replication.From1 Nov 2015 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
- iKap: Targeting nucleocytoplasmic transport for novel anti-cancer therapy.From1 Oct 2015 → 30 Nov 2019Funding: SBO (Strategic basic research)
Publications
1 - 10 of 41
- TRPM3-A Promising Target for Analgesic Treatment(2014)
Authors: Katharina Held, Silvia Joao Pinto, Sara Kerselaers, Katrien De Clercq, Patrick Chaltin, Thomas Voets, Joris Vriens
Pages: 754 - Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects(2018)
Authors: Nihed Draoui, Patrick Chaltin
- Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)
Authors: Patrick Chaltin
- Identification of novel FLT3 kinase inhibitors(2013)
Authors: Amuri Kilonda, Patrick Chaltin, Arnaud Marchand, Jan Cools
Pages: 713 - 21 - Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization(2012)
Authors: Frauke Christ, Jonas Demeulemeester, Belete Ayele Desimmie, Arnaud Marchand, Wim Smets, Patrick Chaltin, Zeger Debyser
Pages: 4365 - 4374 - Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms(2014)
Authors: Nicolas Delattin, Katrijn De Brucker, Katleen Vandamme, Arnaud Marchand, Patrick Chaltin, Bruno Cammue, Karin Thevissen
Pages: 1035 - 1044 - Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin(2014)
Authors: Pieter Spincemaille, Jef Verbeek, Patrick Chaltin, Bruno Cammue, David Cassiman, Karin Thevissen
Pages: 352 - 364 - Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)
Authors: Patrick Chaltin
- Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release(2015)
Authors: Katharina Held, Katrien De Clercq, Arnaud Marchand, Patrick Chaltin, Thomas Voets, Joris Vriens
Pages: E1363 - E1372 - Functional expression and pharmacological modulation of TRPM3 in human sensory neurons(2020)
Authors: Laura Vangeel, Katrien De Clercq, Patrick Chaltin, Catherine Verfaillie, Joris Vriens, Thomas Voets
Pages: 2683 - 2695